The invention generally relates to medical valves and, more particularly, the invention relates to a medical valve having a resilient biasing mechanism.
In general terms, medical valving devices often act as a sealed port that may be repeatedly accessed to non-invasively inject fluid into (or withdraw fluid from) a patient's vasculature. During use, medical personnel may insert a syringe into the proximal port of a properly secured medical valve to inject fluid into (or withdraw fluid from) a patient. Once inserted, the syringe may freely inject or withdraw fluid to and from the patient.
In accordance with one aspect of the invention, a medical valve has an open mode that permits fluid flow, and a closed mode that prevents fluid flow. To that end, the medical valve has a housing with an inlet portion and an outlet portion, a rotating member having a protruding member, and a resilient member with a complimentary surface that mates with the protruding member. The inlet portion and outlet portion of the housing compress the protruding member against the resilient member to bias the valve to the closed mode.
In some embodiments, the housing has an outlet, and the resilient member has a flow path in fluid communication with the outlet. The inlet and outlet portions of the housing may compress the protruding member against the resilient member to seal the flow path of the resilient member in the dosed mode. Specifically, the rotating member may have a member channel that is in fluid communication with the distal opening of the resilient member when in the open mode. Compression of the protruding member against the resilient member thus may seal the member channel when in the open mode (e.g., about the member channel and distal opening).
Further, the resilient member may have a proximally located surface that contacts the inlet portion of the housing. At least a portion of that surface normally is a normal distance from the complimentary surface. The protruding member also may have a given thickness that is greater than the normal distance. Moreover, the resilient member may have an opening distal of the complimentary surface, where the opening permits deformation of the resilient member.
The protruding member may be formed from one member, or first and second protruding members that each respectively contact a first portion of the complimentary surface and a second portion of the complimentary surface. The complimentary surface also may have a third portion between the first and second portions. The first, second, and third portions illustratively normally form a substantially planar surface.
In accordance with another aspect of the invention, a medical valve has a housing with an inlet and an outlet, and a rotating member with a member channel therethrough. The rotating member is rotatable to cause the valve to transition from the closed mode to the open mode after insertion of a medical implement into the inlet. The member channel fluidly communicates the inlet and the outlet when in the open mode. The valve also has a resilient member biasing the rotating member to fluidly disconnect the inlet and the outlet (i.e., biasing the rotating member toward the closed mode). The resilient member has a complimentary portion that mates with the rotating member to substantially prevent longitudinal movement of the rotating member.
In accordance with another embodiment of the invention, a medical valve has a housing with an interior having an inlet, and a rotating member within the interior of the housing. The rotating member has a protruding member with a generally planar mating surface, and a generally planar implement surface that is not parallel with the mating surface. The implement surface is exposed to the inlet to permit contact with a medical implement inserted into the inlet. The valve also has a resilient member with a complimentary surface that mates with the mating surface of the protruding member to bias the rotating member to a closed mode.
Those skilled in the art should more fully appreciate advantages of various embodiments of the invention from the following “Description of Illustrative Embodiments,” discussed with reference to the drawings summarized immediately below.
In illustrative embodiments, a medical valve has a housing formed form an inlet portion and outlet portion that together form an interior containing a valve mechanism. The valve mechanism has a rotating member with a protruding member, and a resilient member with a complimentary surface that mates with the protruding member. The inlet portion and outlet portion of the housing compress the protruding member against the resilient member to bias the valve to the closed mode. Details of illustrative embodiments are discussed below.
After the valve 10 is in place, a nurse, doctor, technician, practitioner, or other user (schematically identified by reference number 20) may intravenously deliver medication to the patient 30, who is lying in a hospital bed. To that end, after the valve is properly primed and flushed (e.g., with a saline flush), the nurse 20 swabs the top surface of the valve 10 to remove contaminants. Next, the nurse 20 uses a medical instrument (e.g., a syringe having a distally located blunt, luer tip complying with ANSI/ISO standards) to inject medication into the patient 30 through the valve 10. For example, the medical practitioner 20 may use the valve 10 to inject drugs such as heparin, antibiotic, pain medication, other intravenous medication, or other fluid deemed medically appropriate. Alternatively, the nurse 20 (or other user) may withdraw blood from the patient 30 through the valve 10.
The medical valve 10 may receive medication or other fluids from other means, such as through a gravity feed system 45. In general, traditional gravity feeding systems 45 often have a bag 50 (or bottle) containing a fluid (e.g., anesthesia medication) to be introduced into the patient 30 hanging from a pole 47. The medical practitioner 20 then connects the bag/bottle 50 to the medical valve 10 using tubing 60 having an attached blunt tip. In illustrative embodiments, the blunt tip of the tubing has a luer taper that complies with the ANSI/ISO standard. After the tubing 60 is connected to the medical valve 10, gravity (or a pump) causes the fluid to begin flowing into the patient 30. In some embodiments, the feeding system 45 may include additional shut-off valves on the tubing 60 (e.g., stop-cock valves or clamps) to stop fluid flow without having to disconnect the tubing 60 from the valve 10. Accordingly, the valve 10 can be used in long-term “indwell” procedures.
After administering or withdrawing fluid from the patient 30, the nurse 20 should appropriately swab and flush the valve 10 and catheter 70 to remove contaminants and ensure proper operation. As known by those skilled in the art, there is a generally accepted valve swabbing and flushing protocol that should mitigate the likelihood of infection. Among other things, as summarized above, this protocol requires proper flushing and swabbing before and after the valve is used to deliver fluid to, or withdraw fluid from the patient.
In this context, fluid displacement generally refers to the flow of fluid through the distal port 120 of the valve 10 (discussed below). Accordingly, a positive fluid displacement generally refers to fluid flowing in a distal direction through the distal port 120, while a negative fluid displacement generally refers to a fluid flowing in a proximal direction through the distal port 120. The positive/neutral nature of the valve 10 is discussed in greater detail below. Of course, not all embodiments exhibit this quality. For example, in alternative embodiments, the valve 10 may have a positive fluid displacement when the instrument 40 is inserted, and a negative fluid displacement when the instrument 40 is withdrawn. In fact, the valve 10 can exhibit other positive/negative/neutral fluid displacement qualities upon instrument insertion and withdrawal. For example, the valve 1 could exhibit a positive fluid displacement upon insertion, and a positive fluid displacement upon withdrawal. Accordingly, discussion of positive/neutral is not intended to limit all embodiments of the invention.
It should be noted that the fluid displacements discussed herein refer to the “net” fluid displaced through the distal port 120. Specifically, during insertion or withdrawal of the instrument 40, the actual flow of fluid through the distal port 120 may change direction and thus, fluctuate. However, when considering this fluctuation, the net change in fluid flow through the distal port 120 should be 1) positive when the valve exhibits a “positive fluid displacement,” and 2) negative when the valve exhibits a “negative fluid displacement.” In a similar manner, a substantially neutral fluid displacement occurs when, as noted above, the valve 10 has a net fluid displacement of about plus or minus one microliter. Of course, the fluid displacement of the valve 10 is discussed herein in terms of one stroke of the instrument 40 (i.e., insertion or withdrawal of the instrument 40).
Ideally, a valve with a neutral displacement has 0.0 microliters of positive or negative fluid displacement. As suggested above, however, in practice, a neutral displacement actually can have a very slight positive or negative displacement (e.g., caused by a manufacturing tolerance), such as a displacement on the order of positive or negative one microliter, or less. In other words, in such embodiments, the volumes of fluid forced through the distal port 120 in a neutral displacement valve are negligible (ideally zero microliters) and should have a negligible impact on the goals of the valve.
Some embodiments may have a positive fluid displacement upon insertion, but a very low positive fluid displacement or very low negative fluid displacement upon withdrawal. For example, such valves 10 may have a negative fluid displacement of about one to two microliters (i.e., about one to two microliters of fluid drawback, which is proximally directed), or about one to two microliters positive fluid displacement (i.e., about one to two microliters of positively pushed fluid, which is distally directed). Although such amounts are in the positive or negative fluid displacement ranges, they still should represent a significant improvement over valves that exhibit higher positive or negative fluid displacements upon withdrawal.
The neutral, positive, or negative fluid displacement of a valve may be corrupted by manual handling of the valve 10, catheter 70 or the instrument 40 during the fluid transfer. For example, a slight inward force applied to the shaft of the syringe 40 (e.g., by the nurse's hand when simply holding the syringe 40) can have the effect of adding a positive fluid displacement from the syringe (when the force is applied) and, ultimately, through the valve 10. In fact, releasing this force from the syringe 40 actually may draw fluid proximally, causing a negative fluid displacement that further corrupts fluid displacement. These effects, however, should not be considered when determining the nature of fluid displacement through the distal port 120. To overcome the problem noted above with regard to squeezing the syringe shaft, for example, the nurse 20 can hold another part of the syringe that does not contain the fluid (e.g., stubs at the proximal end of the syringe 40).
To accomplish these desired goals, the valve 10 has a housing 100 forming an interior having a proximal port 110 for receiving the instrument 40, and the noted distal port 120 having the discussed fluid displacement properties. The valve 10 has an open mode that permits fluid flow through the valve 10, and a closed mode that prevents fluid flow through the valve 10. To that end, the interior contains a valve mechanism that selectively controls. (i.e., allow/permits) fluid flow through the valve 10. The fluid passes through a complete fluid path that extends between the proximal port 110 and the distal port 120.
It should be noted that although much of the discussion herein refers to the proximal port 110 as an inlet, and the distal port 120 as an outlet, the proximal and distal ports 110 and 120 also may be respectively used as outlet and inlet ports. Discussion of these ports in either configuration therefore is for illustrative purposes only.
The valve 10 is considered to provide a low pressure seal at its proximal end 110. To that end, the proximal end 110 of the medical valve 10 has a resilient proximal gland 80 with a resealable aperture 130 that extends entirely through its profile. The aperture 130 may, for example, be a pierced hole or a slit. Alternatively, the proximal gland 80 may be molded with the aperture 130. When the valve 10 is in the closed mode, as shown in
As suggested above, the proximal gland 80 is flush with or extends slightly above the exterior inlet face 140 of the inlet housing 160 (
The outside surface of the valve proximal end 110 may also have inlet threads 90 for connecting the medical instrument 40. Alternatively or in addition, the proximal end may have a slip design for accepting instruments 40 that do not have a threaded interconnect. In a similar manner, the distal end of the valve 10 has a skirt 150 containing threads 280 (see
Generally, unlike the low pressure seal formed by the proximal gland 80, the internal valve mechanism should be capable of withstanding relatively high pressures. Accordingly, this internal valve mechanism is referred to as a “high pressure seal.” To that end, the internal valve mechanism includes a moveable member 180 that cooperates with a resilient member 230 (without limiting scope, hereinafter referred to as “internal gland 230” for convenience) to selectively open and close the fluid channel through the housing 100. In the embodiment shown in
Accordingly, as noted above, the valve 10 may be considered to have dual seals—a low pressure seal at the proximal end, and a high pressure seal within the interior. As an example, when used in the manner shown in
In alternative embodiments, the rotating member 180 is formed from a relatively resilient material, while a relatively rigid member is substituted for the internal gland 230. It also should be noted, however, that some embodiments use other types of movable members that are not primarily rotationally movable. For example, in those embodiments, the movable member may slide linearly. Accordingly, in such embodiments, a moveable member that is capable of selectively permitting fluid flow in the defined manner should be considered to be within the scope of this invention.
Although not clearly shown in
In addition to the proximally exposed surface 200 and substantially hemispherical surface 190, the rotating member 180 also has a pair of a protruding members 210 that are not parallel to the proximally exposed surface 200. The protruding members 210 help support the rotating member 180 within the internal gland 230, and, as discussed in greater detail below, aid in biasing the rotating member 180 toward the closed position. To facilitate fluid flow through the fluid channel, the rotating member 180 also has a through channel 220 that, when in the open mode, channels fluid flow through the rotating member 180 and the valve 10.
The internal gland 230 has a recessed surface 240 for receiving and supporting the rotating member 180. When in the closed mode, the internal gland 230 covers the distal outlet 222 of the channel 220 through the rotating member 180. By covering the distal outlet 222 of the channel 220, the internal gland 230 may not necessarily seal at that point. In other words, fluid still may leak from the channel 220 and traverse along the recessed surface 240. As discussed below, the internal gland 230 has an additional sealing feature (e.g., a flange 294 in one embodiment, discussed below) to prevent such fluid leaking to or from the channel 220 from entering the portion of the fluid path in communication with the distal port 120.
In alternative embodiments, however, the internal gland 230 does seal the distal outlet 222 of member channel 220 when the valve 10 is in the dosed position. To that end, the internal gland 230 may be molded to have a relatively tight fit at that point. Such a fit, however, may increase the resistance of opening and closing the valve 10.
Moreover, in preferred embodiments, the recessed surface 240 effectively is a concavity that generally conforms to the radius of the hemispherical surface 190 of the rotating member 180. In other words, the radius of the hemispherical surface 190 is about the same as the radius of the recessed surface 240 to effectively form a close, registration fit. Other embodiments, however, do not have this relationship. In those cases, the concavity 240 can have a different radius that that of the hemispherical surface 190 (e.g., smaller or larger), or may be a different shape (e.g., elliptical, oval, etc. . . . ). Operation of and various features of the rotating member 180 and the internal gland 230 are discussed in greater detail below.
As discussed above,
Alternative manufacturing techniques, however, can reduce the total number of components, and therefore simplify assembly. In particular, the proximal gland 80 and the inlet housing 160 can be manufactured in a “two-shot” or “over-mold” process. As known by those in the art, the two-shot manufacturing process creates one piece formed with two materials (i.e., the elastomeric proximal gland 80 material and the material forming the rigid inlet housing 160) that are chemically bonded to one another. In a similar manner, the internal gland 230 and the outlet housing 170 can be manufactured in a two-shot process to form a one-piece bottom housing. Therefore, the “two-shot” manufacturing process can reduce the total number of valve components to as few as three, significantly reducing assembly complexity. In addition, use of a two-shot process can significantly minimize the possibility of fluid leaking between the proximal gland 80 and inlet housing 160. In a similar manner, use of a two shot process can significantly minimize the possibility of fluid leaking between the internal gland 230 and the outlet housing 170.
This figure also details a number of additional features of the valve 10. In particular, it shows components that, when in the open mode, ultimately make up the flow path through the housing 100. The flow path begins at the inlet port 110 and into the interior chamber, through the member channel 220, and extends through a member flowpath 290, which is formed through the internal gland 230. As discussed in greater detail below, the proximal opening 292 of the member flowpath 290 has a flange 294 that effectively seals about the periphery of the flowpath 290. The ultimate flowpath extends through an outlet channel 122 that terminates at the distal port 120.
Insertion of a medical instrument 40 into the proximal port 110 opens aperture 130 in the proximal gland 80 (
During insertion, the proximally exposed surface 200 of the rotating member 180 acts as a camming surface against the medical instrument 40. Distally directed force applied to the proximally exposed surface 200 at surface A by the medical instrument 40 begins to rotate the rotating member 180 toward the open position/mode. Specifically, the rotating member 180 rotates about an axis that is generally orthogonally aligned with the longitudinal axis of the valve 10. This force at surface A effectively forms a lever arm extending between surface A and the point of rotation. When the force applied by this effective lever arm overcomes the bias force applied by the interior gland 230, the rotating member 180 begins rotating counter-clockwise toward the open mode.
In general, the rotating member 180 does not move longitudinally. However, some incidental longitudinal movement may occur as the result of slight compression of the valve materials.
Also while moving between modes, the generally hemispherically shaped surface 190 of the rotating member 180 slides along the corresponding portion of the internal gland 230. While sliding, as noted above, the member channel 220 may not be fully sealed. Fluid leaking from the member channel 220, if any, should be blocked from passing through the flowpath 290 by the flange 294.
The rotating member 180 continues to rotate, sliding along the internal gland 230, until the leading edge 226 of the distal opening 222 of the member channel 220 almost passes the leading edge 296 of the flange 294 (
The rotating member 180 continues to rotate to the fully open position shown in
In accordance with illustrative embodiments, when the instrument 40 moves longitudinally at a constant rate, the rotating member 180 rotates at a changing rate (i.e., an increasing or decreasing rate, depending on the direction of movement of the instrument 40). In other words, the rotating member 180 rotates at a changing rate per longitudinal inch of movement of the instrument 40. Specifically, if the instrument 40 were inserted distally at a constant rate, the rotating member 180 would rotate at an increasing rate until the instrument 40 reaches its maximum insertion. In a corresponding manner, if the instrument 40 were withdrawn proximally at a constant rate, the rotating member 180 would rotate at an decreasing rate until the instrument 40 loses contact with the proximally facing surface 200.
In either case, the rotational speed of the rotating member 180 is at its maximum when in the fully open position. Accordingly, the distal opening 222 of the member channel 220 moves most rapidly as it rotates from the open mode (
The rotating member 180 and internal gland 230 cooperate to cause this relationship between instrument insertion and rotating member rotation. Among other things, as noted above, as the medical instrument 40 moves longitudinally into the medical valve 10, the point at which the tip contacts the proximally exposed surface 200 changes. This change in point of contact changes the size of the above noted effective lever arm causing rotational movement. More specifically, as the point of contact moves closer to the center of the rotating member 180, the lever arm decreases, increasing the angular rate of rotation. In addition, the bias force of the interior gland 230 ensures that, at anticipated withdrawal speeds, the surface 200 maintains contact with the instrument 40 during withdrawal (except, of course, after the instrument 40 is withdrawn proximal of the position shown in
This varying speed has a significant performance benefit. Specifically, the instrument 40 is drawn back a minimum distance to close the distal opening 222. Fluid drawback (i.e., negative fluid displacement), if any, through the distal port 120 therefore should be negligible because the instrument 40 moves a relatively short distance within the interior before the valve 10 closes. Accordingly, if properly configured, this should result in a substantially negligible fluid displacement (i.e., between about −1 and +1 microliters) through the distal port 120 of the valve 10.
Moreover, as shown in
As shown in
In some embodiments, the rotating member 180 may also include a generally straight-walled portion 215 near its top, as shown in
The protruding members 210 also may be off-set from the center of the rotating member 180. For example, as shown in
In various figures, the proximally exposed surface 200 is substantially uninterrupted (e.g., no channels or grooves). However, in alternative embodiments, the proximally exposed surface 200 may include grooves 810A and 810B (
As mentioned above and shown in
As the member channel 220 transitions from the inlet 224 toward the distal opening 222, the channel 220 has a generally distally decreasing inner dimension. In other words, as the channel 220 transitions from inlet 224 toward the distal opening 222, the cross-sectional area of substantially the majority of the channel 220 generally decreases. This decrease may be gradual (e.g., a taper), stepped, irregular, or some other configuration.
In some embodiments, the distal opening 222 of the channel 220 is a different size and/or shape than that of the inlet 224. In accordance with illustrative embodiments of the invention, the distal opening 222 of the member channel 220 is configured to maximize fluid flow while permitting a relatively quick valve shut-off capability. To that end, as shown in
To those ends, the distal opening 222 may take on a number of shapes. Among others, it may be elliptical and configured so that its major axis is generally orthogonal to the direction of the rotational movement, and its minor axis is generally parallel to the direction of the rotational movement. In this orientation, the major axis provides the noted high fluid flow rate through the channel 220, while the minor axis allows for quick opening and closing, as described below. Although, an elliptical distal opening 222 is described, other shapes may be used to provide the same results. For example, among other shapes, the distal opening 222 may be substantially rectangular, rectangular with rounded corners, or oval. In some embodiments, the major axis may be about two or more times the length of the minor axis.
As best shown in
Moreover, as also shown in
The rotating member 180 mates with and is supported by the internal gland 230, which is schematically shown in
As noted above, the internal gland 230 normally has a flange 294 generally surrounding the proximal opening 292 of the gland fluid path 290. In this context, the term “normally” is used to connote the shape of a resilient member (e.g., the internal gland 230) when not subjected to external forces (e.g., when the internal gland 230 is separated from the valve 10). For example,
Specifically, the flange 294 normally not only protrudes upwardly into the concavity 240, it also protrudes out over the proximal opening 292 of the member flow path 290. As a result, both normally and when within the valve 10, the flange 294 narrows the proximal opening 292 as compared to the remainder of the flow path 290. As described in greater detail below, the flange 294 seals against the hemispherical surface 190 of the rotating member 180 as the valve 10 transitions between modes. Accordingly, when in the closed mode of
In a corresponding manner, when in the open mode of
The internal gland 230 also has a mating surface 250 that mates with the wings 210 of the rotating member 180. The mating surface 250 may be recessed from the top surface 255 of the internal gland 230 to create vertical walls 257 between the top surface 255 and the mating surface 250. In a preferred embodiment, the wings 210 sit at surfaces B and C, which are considered “complimentary portions” of the internal gland 230 (i.e., complimentary to the wings 210). These surfaces B and C support the rotating member 180 within the internal gland 230 and cooperate to provide the bias to the rotating member 180. Specifically, the edges 211 of wings 210 preferably maintain contact with the vertical walls 257 at all times, even as the valve 10 transitions between open and closed. Alternatively, some embodiments have no such constant contact. Moreover, as known by those in the art, silicone is not compressible. Accordingly, the internal gland 230 has a pair of recesses 310 below surfaces B and C that allow gland material (e.g., above the recesses 310) to deform into their space as the valve 10 transitions from the open to the dosed mode.
Assembly processes position the rotating member 180 in the concavity 240 of the internal gland 230 so that the hemispherical surface 190 of the rotating member 180 sits within the cavity 240 and the wings 210 sit at surfaces B and C above the gland member recesses 310. The wings 210 are oriented so that the bottom surface 212 of each wing 210 lies flat on the mating surface 250, thus causing the proximally exposed surface 200 of the rotating member 180 to be proximally exposed and positioned at the above noted angle (see
In certain embodiments, the wings 210 may be thicker than the height of the vertical walls 257. In such embodiments, the inlet and outlet housings 160 and 170 slightly compress the wings 210 into gland material when the valve 10 is assembled. This creates a seal between the bottom surface 212 of the wings 210 and the mating surface 250, which prevents fluid leakage. This connection also holds the rotating member 180 in place to seal the distal opening 222 of the rotating member 180 in the closed mode, and the member channel 290 when in the closed mode.
As an example, the rotating member 180 and internal gland 230 may be designed so that the wings 210 extend a small distance (e.g., about 0.005 inches) above the mating surface 255 when the valve 10 is not fully assembled. When the inlet and outlet housings 160 and 170 are coupled, the rotating member 180 will compress slightly into the gland material in the cavity 240, causing the bottom surface 212 of the wings 210 to contact the mating surface 250. This also creates a seal between the hemispherical surface 190 of the rotating member 180 and the concavity 240.
In certain embodiments, the mating surface 250 and the vertical walls 257 may be in the form of a C-shaped grove 320 cut into the top surface 255 of the internal gland 230.
As noted above and shown in
Referring back to
The hemispherical surface 190 of the rotating member 180 will continue to slide along the surface of the cavity 240 until the valve 10 is fully open, and the member channel 220 fluidly communicates with the member fluid path 290. When the valve 10 is in the open mode, the flange 294 surrounding the member fluid path 290 creates a seal around the member channel 220, preventing fluid leakage between the rotating member 180 and the internal gland 230, and back through the valve 10.
After connecting the valve 10 to the patient 30, the medical practitioner 20 swabs the valve proximal port 110 and inserts the medical instrument 40 into the proximal port 110 (step 720). Connection and insertion of the medical instrument 40 creates a positive displacement at the distal port 120 of the medical valve 10. As the medical practitioner 20 moves the medical instrument distally (step 730) into the medical valve 10, the tip of the instrument 40 slides along the proximally exposed surface 200 of the rotating member 180 to rotate the rotating member 180. The rotating member 180 continues to rotate until the member channel 220 is in fluid communication with the fluid path 290. At this point, the proximal port 110 and distal port 120 are also in fluid communication, and the valve 10 is open.
As noted above, the valve 10 requires a relatively low prime volume because medical instruments 40 used to open the medical valve 10 take up most of the volume within the medical valve 10 (see
Once the valve 10 is open and the proximal port 110 and distal port 120 are in fluid communication, the medical practitioner 20 can transfer fluids to or from the patient (step 740). For example, if the medical practitioner 20 wishes to administer a medication to the patient 30, he/she may depress the syringe plunger and transfer the medication into the patient 30. Alternatively, the medical practitioner 20 may withdraw blood from the patient 30.
After completing the fluid transfer(s), the medical practitioner 20 can remove the medical instrument (step 750). As discussed above, the medical practitioner 20 should take care not to squeeze the sides of the syringe or medical instrument 40. Doing so may create a positive or negative displacement at the distal port 120 of the medical valve 10. If done properly, removal of the medical instrument 40 should result in a substantially neutral displacement at the valve distal port 120.
As discussed above with reference to
It should be noted that the above embodiments describe a medical valve 10 in which the proximal port 110 and the distal port 120 are aligned with one another. However, in various other embodiments of the present invention, the medical valve 10 can include a Y-site branch 100A (e.g., see
It is also important to note that the embodiments discussed above refer to the use of the medical valve 10 in patient or hospital type setting. However, the medical valve 10 can also be used in the bio-pharmaceutical industry or other non-patient setting. For example, a technician 20 can use valve 10 as an injection or aspiration site in a bio-pharmaceutical manufacturing or R&D process.
In addition, as noted above, although most of the embodiments above describe a rotating member 180 made from a rigid material and a internal gland 230 made from a resilient or elastomeric material, the material characteristics may be reversed. For instance, the rotating member 180 can be a resilient material while the gland may be a rigid material. In such embodiments, the valve operation will be very similar in many respects, but complimentary to that discussed. For example, the interaction between the wings 210 and the mating surface 250 on the internal gland 230 differ. Specifically, instead of the rigid wings 210 deforming the elastomeric gland material into the recesses 310, the rigid gland material will deform the elastomeric wings. However, the gland will still bias the valve 10 toward the closed position. The deformation of the wings 210 will create the spring force, rather than the gland material deformation.
As shown in
As shown in
Although the above discussion discloses various exemplary embodiments of the invention, it should be apparent that those skilled in the art can make various modifications that will achieve some of the advantages of the invention without departing from the true scope of the invention.
This patent application claims priority from provisional U.S. patent applications: Application No. 60/790,914, filed Apr. 11, 2006, entitled, “ROTATIONAL MEDICAL VALVE,” and naming Todd S. Vangsness and Jeffrey F. Kane as inventors, the disclosure of which is incorporated herein, in its entirety, by reference. Application No. 60/837,442, filed Aug. 11, 2006, entitled, “ROTATIONAL MEDICAL VALVE,” and naming Todd S. Vangsness and Jeffrey F. Kane as inventors, the disclosure of which is incorporated herein, in its entirety, by reference. Application No. 60/883,674, filed Jan. 5, 2007, entitled, “ROTATIONAL MEDICAL VALVE,” and naming Jeffrey F. Kane, Todd S. Vangsness, and Ian Kimball as inventors, the disclosure of which is incorporated herein, in its entirety, by reference. This patent application is related to the following co-pending U.S. patent applications: U.S. patent application Ser. No. 11/786,413, entitled, “MEDICAL VALVE WITH ROTATING MEMBER AND METHOD,” naming Todd S. Vangsness, Jeffrey F. Kane, and Ian Kimball as inventors, filed on even date herewith, now U.S. Pat. No. 7,815,168, the disclosure of which is incorporated herein, in its entirety, by reference. U.S. patent application Ser. No. 11/786,457, entitled, “MEDICAL VALVE WITH RESILIENT SEALING MEMBER,” naming Jeffrey F. Kane, Ian Kimball, and Todd S. Vangsness as inventors, filed on even date herewith, now U.S. Pat. No. 7,879,012, the disclosure of which is incorporated herein, in its entirety, by reference. U.S. patent application Ser. No. 11/786,425, entitled, “MEDICAL VALVE WITH MOVABLE MEMBER,” naming Ian Kimball, Todd S. Vangsness, and Jeffrey F. Kane as inventors, filed on even date herewith, now U.S. Pat. No. 7,857,284, the disclosure of which is incorporated herein, in its entirety, by reference. U.S. patent application Ser. No. 11/786,452, entitled, “ANTI-DRAWBACK MEDICAL VALVE AND METHOD,” naming Todd S. Vangsness, Jeffery F. Kane, and Ian Kimball as inventors, filed on even date herewith, now U.S. Pat. No. 8,002,755, the disclosure of which is incorporated herein, in its entirety, by reference.
Number | Name | Date | Kind |
---|---|---|---|
2705501 | Frizsch et al. | Apr 1955 | A |
2919935 | Nyberg | Jan 1960 | A |
3087492 | Garth | Apr 1963 | A |
3192949 | DeSee | Jul 1965 | A |
3279497 | Supinger et al. | Oct 1966 | A |
3385301 | Harautuneian | May 1968 | A |
3399677 | Gould et al. | Sep 1968 | A |
3423063 | German | Jan 1969 | A |
3618892 | Sciuto, Jr. | Nov 1971 | A |
3806086 | Cloyd | Apr 1974 | A |
3831629 | Mackal et al. | Aug 1974 | A |
3838843 | Bernhard | Oct 1974 | A |
3921656 | Meisenheimer et al. | Nov 1975 | A |
3923065 | Nozick et al. | Dec 1975 | A |
3965910 | Fischer | Jun 1976 | A |
4063555 | Ulinder | Dec 1977 | A |
4080965 | Phillips | Mar 1978 | A |
4116201 | Shah | Sep 1978 | A |
4143853 | Abramson | Mar 1979 | A |
4181149 | Cox | Jan 1980 | A |
4223808 | Williams et al. | Sep 1980 | A |
4324239 | Gordon et al. | Apr 1982 | A |
4335747 | Mitsumoto et al. | Jun 1982 | A |
4344435 | Aubin | Aug 1982 | A |
4421296 | Stephens | Dec 1983 | A |
4445664 | Allread | May 1984 | A |
4473211 | Fremy | Sep 1984 | A |
4496348 | Genese et al. | Jan 1985 | A |
4535820 | Raines | Aug 1985 | A |
4627598 | Fremy | Dec 1986 | A |
4664149 | Fremy | May 1987 | A |
4675003 | Hooven | Jun 1987 | A |
4683905 | Vigneau et al. | Aug 1987 | A |
4683916 | Raines | Aug 1987 | A |
4710168 | Schwab et al. | Dec 1987 | A |
4712583 | Pelmulder et al. | Dec 1987 | A |
4743235 | Waldbillig et al. | May 1988 | A |
4745950 | Mathieu | May 1988 | A |
4752287 | Kurtz et al. | Jun 1988 | A |
4809679 | Shimonaka et al. | Mar 1989 | A |
4819684 | Zaugg et al. | Apr 1989 | A |
4830331 | Vindum | May 1989 | A |
4905965 | Dolev | Mar 1990 | A |
4915687 | Sivert | Apr 1990 | A |
4917668 | Haindl | Apr 1990 | A |
4944329 | Cardin et al. | Jul 1990 | A |
5006114 | Rogers et al. | Apr 1991 | A |
5041087 | Loo et al. | Aug 1991 | A |
5049128 | Duquette | Sep 1991 | A |
5050841 | Jacobsson | Sep 1991 | A |
5080654 | Picha et al. | Jan 1992 | A |
5085645 | Purdy et al. | Feb 1992 | A |
5090448 | Truchet | Feb 1992 | A |
5098394 | Luther | Mar 1992 | A |
5100394 | Dudar et al. | Mar 1992 | A |
5108380 | Herlitze et al. | Apr 1992 | A |
5147333 | Raines | Sep 1992 | A |
5171230 | Eland et al. | Dec 1992 | A |
5203775 | Frank et al. | Apr 1993 | A |
5215538 | Larkin | Jun 1993 | A |
5230706 | Duquette | Jul 1993 | A |
5242393 | Brimhall et al. | Sep 1993 | A |
5242432 | DeFrank | Sep 1993 | A |
5269771 | Thomas et al. | Dec 1993 | A |
5295657 | Atkinson | Mar 1994 | A |
5300034 | Behnke et al. | Apr 1994 | A |
5330435 | Vaillancourt | Jul 1994 | A |
5342326 | Peppel et al. | Aug 1994 | A |
5360413 | Leason et al. | Nov 1994 | A |
5380306 | Brinon | Jan 1995 | A |
5390898 | Smedley et al. | Feb 1995 | A |
5397314 | Farley et al. | Mar 1995 | A |
5401255 | Sutherland et al. | Mar 1995 | A |
5403284 | Gross | Apr 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5458640 | Gerrone | Oct 1995 | A |
5465938 | Werge et al. | Nov 1995 | A |
5474536 | Bonaldo | Dec 1995 | A |
5474544 | Lynn | Dec 1995 | A |
5489274 | Chu et al. | Feb 1996 | A |
5509433 | Paradis | Apr 1996 | A |
5509912 | Vaillancourt et al. | Apr 1996 | A |
5520666 | Choudhury et al. | May 1996 | A |
5533708 | Atkinson et al. | Jul 1996 | A |
5533983 | Haining | Jul 1996 | A |
5540661 | Tomisaka et al. | Jul 1996 | A |
5549566 | Elias et al. | Aug 1996 | A |
5569235 | Ross et al. | Oct 1996 | A |
5573516 | Tyner | Nov 1996 | A |
5578059 | Patzer | Nov 1996 | A |
5616129 | Mayer | Apr 1997 | A |
5616130 | Mayer | Apr 1997 | A |
5620434 | Brony | Apr 1997 | A |
5674206 | Allton et al. | Oct 1997 | A |
5676346 | Leinsing | Oct 1997 | A |
5685866 | Lopez | Nov 1997 | A |
5694686 | Lopez | Dec 1997 | A |
5695466 | Lopez et al. | Dec 1997 | A |
5699821 | Paradis | Dec 1997 | A |
5700248 | Lopez | Dec 1997 | A |
5730418 | Feith et al. | Mar 1998 | A |
5749861 | Guala et al. | May 1998 | A |
RE35841 | Frank et al. | Jul 1998 | E |
5782816 | Werschmidt et al. | Jul 1998 | A |
5806831 | Paradis | Sep 1998 | A |
5820601 | Mayer | Oct 1998 | A |
5921264 | Paradis | Jul 1999 | A |
5947954 | Bonaldo | Sep 1999 | A |
6029946 | Doyle | Feb 2000 | A |
6036171 | Weinheimer et al. | Mar 2000 | A |
6039302 | Cote, Sr. et al. | Mar 2000 | A |
6048335 | Mayer | Apr 2000 | A |
6050978 | Orr et al. | Apr 2000 | A |
6063062 | Paradis | May 2000 | A |
6068011 | Paradis | May 2000 | A |
6079432 | Paradis | Jun 2000 | A |
6089539 | Kouda | Jul 2000 | A |
6089541 | Weinheimer et al. | Jul 2000 | A |
6090074 | Brimhall et al. | Jul 2000 | A |
6142446 | Leinsing | Nov 2000 | A |
6152900 | Mayer | Nov 2000 | A |
6206860 | Richmond | Mar 2001 | B1 |
6228069 | Barth et al. | May 2001 | B1 |
6245048 | Fangrow, Jr. et al. | Jun 2001 | B1 |
6290206 | Doyle | Sep 2001 | B1 |
6364869 | Bonaldo | Apr 2002 | B1 |
6422267 | Makishima et al. | Jul 2002 | B1 |
6485472 | Richmond | Nov 2002 | B1 |
6491668 | Paradis | Dec 2002 | B1 |
6543745 | Enerson | Apr 2003 | B1 |
6595964 | Finley et al. | Jul 2003 | B2 |
6598620 | Fremy | Jul 2003 | B1 |
6609696 | Enerson | Aug 2003 | B2 |
6669673 | Lopez | Dec 2003 | B2 |
6779777 | Kouda | Aug 2004 | B2 |
6827329 | Mikiya et al. | Dec 2004 | B2 |
6899132 | Mikiya et al. | May 2005 | B2 |
6964406 | Doyle | Nov 2005 | B2 |
7028982 | Kohda | Apr 2006 | B2 |
7056308 | Utterberg | Jun 2006 | B2 |
7063685 | Rome | Jun 2006 | B2 |
7070164 | Kohda | Jul 2006 | B2 |
7114701 | Peppel | Oct 2006 | B2 |
7118560 | Bonaldo | Oct 2006 | B2 |
7131458 | Kohda | Nov 2006 | B2 |
7184825 | Leinsing et al. | Feb 2007 | B2 |
7314061 | Peppel | Jan 2008 | B2 |
7329249 | Bonaldo | Feb 2008 | B2 |
7343931 | Packham | Mar 2008 | B2 |
7510545 | Peppel | Mar 2009 | B2 |
7815168 | Vangsness et al. | Oct 2010 | B2 |
7857284 | Kimball et al. | Dec 2010 | B2 |
7879012 | Kane et al. | Feb 2011 | B2 |
8002755 | Vangsness et al. | Aug 2011 | B2 |
20030050610 | Newton et al. | Mar 2003 | A1 |
20030093061 | Ganem | May 2003 | A1 |
20030098430 | Leinsing et al. | May 2003 | A1 |
20030141477 | Miller | Jul 2003 | A1 |
20040073171 | Rogers et al. | Apr 2004 | A1 |
20050087239 | Kohda | Apr 2005 | A1 |
20050087241 | Kohda | Apr 2005 | A1 |
20050256457 | Rome | Nov 2005 | A1 |
20060178645 | Peppel | Aug 2006 | A1 |
20070218757 | Guala | Sep 2007 | A1 |
20080172003 | Plishka et al. | Jul 2008 | A1 |
20080190485 | Guala | Aug 2008 | A1 |
Number | Date | Country |
---|---|---|
0 629 418 | Dec 1994 | EP |
1 264 890 | Feb 1972 | GB |
01-099568 | Apr 1989 | JP |
2003-245362 | Sep 2003 | JP |
2004-211739 | Jul 2004 | JP |
WO 8302559 | Aug 1983 | WO |
WO 9739791 | Oct 1997 | WO |
WO 9822178 | May 1998 | WO |
WO 9826835 | Jun 1998 | WO |
WO 9839594 | Sep 1998 | WO |
WO 0044433 | Aug 2000 | WO |
WO 03018104 | Mar 2003 | WO |
WO 03018105 | Mar 2003 | WO |
WO 2004006046 | Jan 2004 | WO |
Entry |
---|
Jøgen Olsen, Authorized officer Intellectual Property Office of Singapore, Search and Examination Report—Application No. 200807555-8, dated Nov. 19, 2010 (10 pages). |
Japanese Patent Office, Official Action—Application No. 2009-505422, dated Jan. 27, 2012 (4 pages). |
Japanese Patent Office, Official Action (Notice of Reasons for Rejection)—Application No. 2009-505422, dated Jan. 27, 2012 (6 pages) [English Translation]. |
Number | Date | Country | |
---|---|---|---|
20070238337 A1 | Oct 2007 | US |
Number | Date | Country | |
---|---|---|---|
60790914 | Apr 2006 | US | |
60837442 | Aug 2006 | US | |
60883674 | Jan 2007 | US |